Document is current
Any future updates will be listed below
-
Authors
Bhattacharyya, Anuradha
Trotta, Christopher R. https://orcid.org/0000-0001-5749-0133
Narasimhan, Jana
Wiedinger, Kari J.
Li, Wencheng
Effenberger, Kerstin A.
Woll, Matthew G.
Jani, Minakshi B.
Risher, Nicole
Yeh, Shirley
Cheng, Yaofeng
Sydorenko, Nadiya
Moon, Young-Choon
Karp, Gary M.
Weetall, Marla
Dakka, Amal
Gabbeta, Vijayalakshmi
Naryshkin, Nikolai A.
Graci, Jason D.
Tripodi, Thomas Jr.
Southwell, Amber
Hayden, Michael
Colacino, Joseph M.
Peltz, Stuart W. https://orcid.org/0000-0002-9158-9142
- License Information
-
More Information
Article History
Received: 17 March 2021
Accepted: 28 October 2021
First Online: 15 December 2021
Competing interests
: Anuradha Bhattacharyya, Amal Dakka, Kerstin A. Effenberger, Vijayalakshmi Gabbeta, Minakshi B. Jani, Wencheng Li, Nikolai Naryshkin, Christopher R. Trotta and Kari J. Wiedinger are inventors in International Application Number PCT/US2018/037412, assigned to PTC Therapeutics, Inc., entitled ‘Methods for Modifying RNA Splicing’, relating to the use of HTT-C1. Anuradha Bhattacharyya, Minakshi B. Jani, Young-Choon Moon and Nadiya Sydorenko are inventors in U.S Patent 10,874,672, assigned to PTC Therapeutics, Inc., entitled ‘Methods for Treating Huntington’s Disease’, relating to the use of HTT-C1. Anuradha Bhattacharyya, Minakshi B. Jani, Nadiya Sydorenko and Matthew G. Woll are inventors in International Application Number PCT/US2018/039775, assigned to PTC Therapeutics, Inc., entitled ‘Methods for Treating Huntington’s Disease’, relating to the use of HTT-D1. Nikolai Naryshkin is an inventor in U.S. Patent 10,195,202, assigned to PTC Therapeutics, Inc., entitled ‘Methods for Modulating the Amount of RNA Transcripts’, relating to the use of HTT-D1. Anuradha Bhattacharyya, Christopher R. Trotta, Jana Narasimhan, Wencheng Li, Kerstin A. Effenberger, Matthew G. Woll, Minakshi Jani, Nicole Risher, Shirley Yeh, Yaofeng Cheng, Nadiya Sydorenko, Young-Choon Moon, Gary M. Karp, Marla Weetall, Amal Dakka, Vijayalakshmi Gabbeta, Jason D. Graci, Thomas Tripodi, Jr., Joseph M. Colacino and Stuart W. Peltz are present employees of PTC Therapeutics, Inc., a biotechnology company. In connection with such employment, the authors received salary, benefits and stock-based compensation, including stock options, restricted stock, other stock-related grants and the right to purchase discounted stock through PTC’s employee stock purchase plan. Kari Wiedinger and Nikolai Naryshkin are former employees of PTC Therapeutics, Inc. and hold stock in the company. Amber Southwell and Michael Hayden declare no competing interests.
